Antacid Market Business Opportunities, Application Analysis, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 – 2025

The global antacid market size is expected to reach USD 7.91 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 3.9% over the forecast period. The trend of self-medication for occasional heartburn is one of the major factors driving the market.

Growing geriatric population is expected to positively impact the overall market for antacid. According to the United Nations Department of Economic And Social Affairs (DESA), the global elderly population (60 years and above), was around 962 million in 2017. This number is expected to grow at the fastest rate in Latin America with 71% increase in population aged 60 and over, followed by Asia with 66%, Africa with 64%, North America with 41%, and Europe with 23%.

Key players operating in antacid market focus on product enhancement to cater to patient requirements, such as changing the dosage form into chewable tablets, powder, and jelly. Also, these players are involved in collaborations and acquisitions to expand their market presence. For instance, in 2017, Pfizer, Inc. entered into a strategic agreement with AstraZeneca to acquire one of the antacid brands, Neksium for a value of INR 75 crores in India to boost its product portfolio.

The easy availability of antacids over-the-counter offer growth opportunities for the sales of overall market. Some of the key players areGlaxoSmithKline plc; AstraZeneca; Pfizer, Inc.; Sun Pharmaceuticals Industries Ltd.; Dr. Reddy’s Laboratories Ltd.; Bayer AG; Takeda Pharmaceutical Company Limited.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/antacids-market

Further key findings from the report suggest:

• In 2017, tablet segment led the antacid market due to high efficacy compared to other dosage forms. Liquid is anticipated to be the fastest growing segment due to its palatable taste and preferred choice for children and elderly population
• Retail pharmacy led the distribution channel segment due its accessibility and availability. Online pharmacy is anticipated to be the fastest growing segment due to growing adoption of Pharma 3.0 and consumer awareness
• Asia Pacific is estimated to be the largest and fastest growing region over the forecast period due to presence of key players such as GlaxoSmithKline plc; Pfizer Inc.; and Abbott among others
• North America held the second largest market share in 2017 owing to increasing prevalence of different digestive disorders
• Some of the key companies operating in this market are GlaxoSmithKline plc; Bayer AG; Boehringer Ingelheim International GmbH; Dr. Reddy’s Laboratories Ltd.; Reckitt Benckiser Group plc; Sun Pharmaceuticals Ltd.; Sanofi; Takeda Pharmaceutical Company Limited; Pfizer Inc.; and Procter & Gamble.

Intravascular Catheters Market Dynamics, Recent and Upcoming Trends, International Players, Demand and Forecast to 2025

The global intravascular catheters market size is expected to reach USD 8.80 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness a CAGR of 11.4% during the forecast years. Increasing usage of catheters in various surgical procedures along with awareness about hospital-acquired infections is projected to propel market growth. Moreover, rise in coverage of healthcare insurance is also estimated to contribute toward the industry growth from 2018 to 2025.

Intravascular Catheters

Increasing cases of trauma injuries and cardiovascular and urological procedures are also expected to drive the demand for intravascular catheters. Short Peripheral Intravascular Catheters (PIVC) led the market with a revenue of USD 2.61 billion in 2017, on account of lower infection risks associated with these products. The segment is expected to witness a lucrative CAGR as a result of increasing concern for catheter-associated bloodstream infections leading to catheter colonization.

Thus, high preference for short PIVCs over its counteparts will drive the segment. Hospital was the dominant end-use segment with a revenue of USD 2.29 billion in 2017 and is expected to continue the trend over the forecast period owing to rising cases of surgical procedures requiring catheters. Moreover, increased concern about hospital-acquired infection and growing health insurance coverage are likely to boost the segment growth further. Ambulatory Surgical Centers (ASCs) are anticipated to witness the fastest growth with a CAGR of 13.1% during the estimated period.

Surgical procedures are cheaper in ASCs as compared to hospitals. Thus, the ASCs segment is expected to witness rapid growth, which will drive the product demand in the years to come. Asia Pacific led the global market with a revenue of USD 1.05 billion in 2017. This growth was attributed to the presence of target population, high investments in healthcare infrastructure, increased insurance coverage, and easy availability of reimbursement.

This region is anticipated to witness a lucrative growth due to high potential to capture unmet medical needs for patients suffering from CVDs, urinary diseases, and trauma injuries. China alone led the regional market in 2017 owing to high unmet medical needs, awareness about hospital-acquired infections, and easy healthcare accessibility.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/intravascular-catheters-market

Further key findings from the study suggest:

• Asia Pacific led the market in 2017 and accounted for a revenue share of USD 1.05 billion in the same year
• The region is estimated to expand further owing due to the presence of target population, increased awareness about hospital-acquired infections, and rise in healthcare coverage
• China is anticipated to be the fastest-growing market in Asia Pacific region with a CAGR of 14.8 % between 2018 and 2025
• Some of the key companies in the market are Boston Scientific Corp.; C.R. Bard, Inc.; Johnson & Johnson Services, Inc.; Abbott Laboratories; Coloplast Ltd.; Smith Medical, Inc.; Edwards Lifesciences Corp.; Medtronic PLC; McKesson Medical Surgical, Inc.; and Terumo Corp.

The Future of Healthcare Antibody Drug Conjugates Market Is Closer Than You Think

The global antibody drug conjugate market size is expected to reach USD 9.93 billion by 2025, according to a new report by Grand View Research, Inc. it is projected to expand at a CAGR of 25.9% over the forecast period. Increasing incidence of cancer coupled with growing geriatric population are likely to drive the market for Antibody-Drug Conjugates (ADC). Furthermore, major technological advancements are also contributing to drive the growth. According to the World Health Organization (WHO), the number of people aged 65 years and above, is projected to reach 16% of the total population by 2050 from 7% in 2000. Aging has become a substantial risk factor for numerous diseases including cancer and others. Hence, the growing geriatric population is expected to drive growth of the market over the forecast period.

Until 2018, four ADCs were available in the market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due to appropriate targeting and improved technology, ADCs have been gaining a lot of attention from both small and large pharmaceutical companies. Currently there are more than 50 ADCs in clinical trials and it has been projected that during the forecast period three to four ADCs will be commercialized in the area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer, breast cancer, and ovarian cancer. It has been observed that the maximum number of clinical trials are being conducted for lymphoma.

Seattle Genetics and Roche are leading the antibody drug conjugate market in terms of market share. Until 2017 only two ADCs were commercially available-Adcetris by Seattle Genetics and Kadcyla by Roche. Recently, two more Pfizer’s products were approved to be marketed for acute myeloid leukaemia and acute lymphoblastic leukaemia. Hence, it has been estimated that over the forecast period, Pfizer is anticipated to gain a significant market share.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market

Further key findings from the report suggest:

• Breast cancer was the largest segment in 2017 and is likely to witness a significant growth over the forecast period due to the factors such as availability of Kadcyla and high prevalence of breast cancer
• Cleavable linker is expected to witness the fastest growth over the forecast period as the maximum product in the pipeline contains cleavable linkers. In addition, in 2017 two new products-Besponsa and Mylotarg were approved in the market
• In 2017, North America was the largest revenue generating region in the antibody-drug conjugates market. It is the most well-established regions in terms of patient awareness and usage of ADCs and makes up most of the existing market
• The players operating in this space are F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
• Market players are adopting strategies, such as introducing technologically advanced products, collaborations, and geographic expansions to increase their market share. For instance, Seattle Genetics collaborated with Takeda for developing brentuximab vedotin (Adcetris) for refractory/relapsed Hodgkin lymphoma.

Fabry Disease Treatment Market Scope and Overview 2019 to 2025

The global fabry disease treatment market size is estimated to reach a value of USD 3.12 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.6% during the forecast period. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market.

Fabry disease is a rare inherited lysosomal storage disorder caused by genetic mutation that interferes with function of alpha galactosidase enzyme. Fabry disease generally has a late onset with mild symptoms, due to which several patients are often undiagnosed. Standard of care for management of the disease is enzyme replacement therapy (ERT). Sanofi’s Fabrazyme and Shire’s Replagal are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has been approved.

Focus of current clinical trials is to improve the safety and efficacy profile of ERTs and introduction of novel oral therapies that can eliminate the need for intravenous infusions. Recently, Amicus Therapeutics’ Galafold has been approved as the first oral chaperone therapy for the treatment of adults in the U.S., Canada, EU, Japan, Australia, Israel, and South Korea.

North America held the largest share in the Fabry disease treatment market in 2017, followed by Europe. The growth of the region can be attributed to higher adoption of novel therapies, favorable reimbursement policies, and better healthcare facilities. However, high cost of therapy with ERTs such as Fabrazyme is an impediment for the market in developing regions.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/fabry-disease-treatment-market

Further Key Findings From the Study Suggest:

• Although the exact prevalence is unknown, Fabry disease affects approximately one in 40,000 males
• The enzyme replacement therapy segment led the market with over 85.0% market share in 2017 due to strong sales of Fabrazyme and Replagal.
• North America commanded the leading market share of more than 45.0% in the Fabry disease treatment market, followed by Europe, in 2017
• APAC is likely to witness the fastest growth during the forecast period, followed by Latin America, due to increasing healthcare expenditure and rising patient population
• Some of the key players in the market are Sanofi S.A.; Shire Plc.; Amicus Therapeutics Inc.; ISU Abxis Co Ltd.; JCR Pharmaceuticals Co Ltd.; Protalix Biotherapeutics Inc.; Idorsia Pharmaceuticals Ltd.; Avrobio Inc.; Greenovation Biotech GmbH; Moderna Therapeutics Inc.; and Green Cross Pharma Pte Ltd.

Hunter Syndrome Treatment Market Overview by Business Manufactures with Forecast Analysis 2019-2025

The global hunter syndrome treatment market size is estimated to reach a value of USD 1.4 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 7.6% during the forecast period. Rising patient population living with Hunter syndrome, increasing healthcare expenses, and potential approval of pipeline drugs worldwide are some of the major factors fueling market growth.

Hunter syndrome, which is also known as mucopolysaccharidosis type II (MPS II), is caused by iduronate-2-sulfatase enzyme deficiency. The treatment mainly focuses on management of symptoms, indications, and disease progression-associated complications, since there is no permanent cure for Hunter syndrome. Existing treatment includes enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT). Disease diagnosis is usually determined by a blood test for iduronate-2-sulfatase deficiency and occurs early in life based on the appearance of skeletal abnormalities.

Enzyme replacement therapy held the largest share among current treatment options in the market. This can be attributed to strong revenue generated by Shire’s ELAPRASE, an ERT prescribed worldwide to improve walking capacity and reduce spleen volume in patients of 5 years of age and older.

North America led the Hunter syndrome treatment market in 2017 with a share of close to 40.0%. This can be attributed to developed healthcare facilities in the region and increased investment in R&D of novel therapies. While novel treatments including ERTs and HSCTs are gaining penetration in developed markets, high cost of therapy poses as a hurdle in developing regions.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/hunter-syndrome-treatment-market

Further key findings from the study suggest:

• Hunter syndrome affects around one per 160,000 males. It is an X-linked recessive disorder and women are far less at a risk of developing this disease
• The enzyme replacement therapy segment acquired the largest share in 2017 and is expected to hold its leading position through the forecast period due to increased adoption of ELAPRASE and potential approval of Hunterase worldwide
• North America dominated the Hunter syndrome treatment market in 2017 due to well-established healthcare infrastructure and favorable reimbursement policies
• The APAC region is expected to witness the fastest growth due to rising disease cohort driven by increasing healthcare expenses
• Some of the key players in the market are Shire Plc.; GC Pharma; JCR Pharmaceuticals Co Ltd.; RegenxBio Inc.; Sangamo Therapeutics; ArmaGen Inc.; Inventiva; Denali Therapeutics Inc.; Esteve; and Bioasis Technologies Inc.

Antisense & RNAi Therapeutics Market 2019 Growth and Opportunities by key players | GSK, Sanofi-Genzyme, Alnylam Pharmaceuticals, Marina Biosciences, Benitec Biopharma

The global antisense and RNAi therapeutics market size is expected to reach USD 1.81 billion by 2025, according to a new report by Grand View Research, Inc., recording a 7.5% CAGR during the forecast period. Rising instances of external funding to conduct clinical studies pertaining to introduction of novel drug moieties plays a vital role in the process of new product development. This, along with ongoing developments in biological vectors and nanotechnology, has fueled market growth.

Multinational healthcare establishments promote awareness and aid in finding novel therapies for treatment of different disorders. Private institutes such as California Institute of Regenerative Medicine and ALS Association are involved in conducting trials by funding research institutes and pharmaceutical organizations and this is expected to significantly fuel sector growth. Moreover, government initiatives for speeding the development of drug delivery platforms in order to reduce disease burden are attributive for industrial growth.

Antisense and RNAi therapeutics services are applicable in treatment of a wide range of diseases that target nucleic acid and affect cell growth cycle. miRNA is attracting considerable interest in its ability to restore gene expression and correct protein production, thereby influencing industrial progress. Developments that involve the research of using different routes to deliver the desired effect of candidate moiety before its removal from blood are anticipated to fuel sector growth.

However, challenges associated with drug delivery are expected to impede growth to a certain extent. Delivery technologies that enable mitigation of off-target effects and undesirable immunological stimulation need to be introduced in order to reduce the effect of restraining factors.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market

Further key findings from the report suggest:

• Antisense RNA technology accounted for the largest share in market revenue in 2017 owing to advantages associated with this technology over RNA interference
• Based on the triggering of RNA molecules, this technology is segmented into siRNA and miRNA. Owing to significant involvement of miRNA in maintaining a cell’s identity, these are used to provide deep insight to cancer metastasis
• Usage of RNAi therapy to selectively target SNPs in genetic disorders is a major factor expected to provide this segment several potential treatment avenues over the forecast period
• siRNA is highly specific and allows induction at advanced stages of cancer growth as compared to chemotherapy, which enables it to emerge as the dominant sub-segment in oncology applications
• Extensive R&D programs carried out to develop an efficient method for the delivery of RNA silencing therapeutic products is anticipated to propel growth. These R&D programs are based on obtaining desired pharmacological action prior to removal of the product from the cytoplasm and systemic circulation
• Isis Pharmaceuticals/ Ionis Pharmaceuticals, GSK, Alnylam Pharmaceuticals, Marina Biosciences, Sanofi-Genzyme, Quark Pharmaceuticals, Gene Signal, and Benitec Biopharma are major companies in the market involved in development and commercialization of products
• Strong product portfolio in different phases of clinical trials and preclinical development programs is expected to contribute to the growth of this industry.

2019 Biopharmaceutical Excipients Market Research By Product (Solubilizers & Surfactants/Emulsifiers, Specialty Excipients, Polyols, Carbohydrates), By Region, And Segment Forecasts to 2025

The global biopharmaceutical excipients market size is expected to reach USD 2.7 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 6.08% over the forecast period. Rapid expansion of the biopharmaceutical industry due to increasing manufacturing capacities is one of the key driving force of this market. Rise in the number of protein therapeutics coupled with the presence of a substantial number of excipients to protect these proteins from degradation is also driving the market growth.

Investigational studies that are implemented for the impact analysis of excipient variability on in vitro dissolution testing are expected to reduce the attrition rate of final products and increase the reproducibility. These studies help scientists in gaining insights on the in vivo functioning and pharmacodynamic analysis of large molecules. The market exhibits continuous need of innovative excipient technologies to prolong the in vivo effectiveness of biologics and for improvement in the product delivery. Moreover, extensive R&D for the development of raw materials that help improve yields in mammalian cell-culture processes is expected to drive the market in future.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-excipients-market

Further key findings from the study suggest:

• Easy availability and wide usage of dextrose, sucrose, and starch in biopharmaceutical formulations has resulted in the largest revenue share of carbohydrates
• Polyols is expected to be the fastest-growing product segment in the global biopharmaceutical excipients market
• This can be attributed to increasing concerns regarding protein degradation, which can be reduced by using polyols
• North America led the global market in 2017 accounting for the largest revenue share as a result of the presence of key biopharmaceutical manufacturers in U.S.
• Emerging markets, such as India and China, are projected to be driven by the contract manufacturers operating in these regions
• Some major biopharmaceutical excipient suppliers are Merck KGaA; Roquette; Clariant; DFE Pharma; SPI Pharma, Inc.; and JRS Pharma LP
• Most of these companies are engaged in establishing partnerships with biopharmaceutical manufacturers to understand their needs and develop raw materials specific to the process and end-product